降氨治疗通过恢复骨骼肌蛋白质稳态逆转肝硬化肌少症
该临床前研究在C2C12鼠肌管及高氨门腔吻合大鼠中观察降氨效果。高氨导致肌管直径减小、蛋白合成受损及自噬流增加,撤除铵后部分逆转。4周降氨治疗(L-鸟氨酸L-天冬氨酸和利福昔明)显著降低血及骨骼肌氨,增加瘦体重、握力、骨骼肌质量与直径及2型纤维。
要点
- 高氨血症导致肌管直径减小、蛋白合成受损和自噬流增加。
- 撤除铵24及48小时后上述肌管改变部分逆转。
- 4周降氨治疗改善门腔吻合大鼠的骨骼肌表型与功能。
核心结论
- 降氨治疗可改善骨骼肌表型和功能及高氨所致的分子扰动;这些临床前研究为长期降氨治疗逆转肝硬化肌少症奠定基础。
研究设计与样本
- 体外研究使用C2C12鼠肌管,先暴露于10 mM醋酸铵24小时,再撤除醋酸铵24及48小时。
- 体内研究使用高氨门腔吻合大鼠及假手术配对喂养Sprague-Dawley大鼠,口服L-鸟氨酸L-天冬氨酸和利福昔明4周。
主要发现
- 高氨环境下肌管直径减小、蛋白合成受损、自噬流增加,撤除醋酸铵24及48小时后部分逆转。
- 4周降氨治疗组较未治疗组血氨和骨骼肌氨显著降低,瘦体重增加,握力改善,骨骼肌质量和直径增加,2型纤维增多。
- 门腔吻合大鼠中升高的骨骼肌肌肉生长抑制素表达、降低的哺乳动物雷帕霉素靶蛋白复合物1功能及高氨应激反应(包括自噬标志物)被降氨治疗逆转。
- 尽管有显著改善,分子和功能读数未被降氨措施完全逆转。
局限性
- 尽管有显著改善,分子和功能读数未被降氨措施完全逆转。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Sarcopenia or skeletal muscle loss is a frequent, potentially reversible complication in cirrhosis that adversely affects clinical outcomes. Hyperammonemia is a consistent abnormality in cirrhosis that results in impaired skeletal muscle protein synthesis and breakdown (proteostasis). Despite the availability of effective ammonia-lowering therapies, whether lowering ammonia restores proteostasis and increases muscle mass is unknown. Myotube diameter, protein synthesis, and molecular responses in C2C12 murine myotubes to withdrawal of ammonium acetate following 24-hour exposure to 10 mM ammonium acetate were complemented by in vivo studies in the hyperammonemic portacaval anastomosis rat and sham-operated, pair-fed Sprague-Dawley rats treated with ammonia-lowering therapy by l-ornithine l-aspartate and rifaximin orally for 4 weeks. We observed reduced myotube diameter, impaired protein synthesis, and increased autophagy flux in response to hyperammonemia, which were partially reversed following 24-hour and 48-hour withdrawal of ammonium acetate. Consistently, 4 weeks of ammonia-lowering therapy resulted in significant lowering of blood and skeletal muscle ammonia, increase in lean body mass, improved grip strength, higher skeletal muscle mass and diameter, and an increase in type 2 fibers in treated compared to untreated portacaval anastomosis rats. The increased skeletal muscle myostatin expression, reduced mammalian target of rapamycin complex 1 function, and hyperammonemic stress response including autophagy markers normally found in portacaval anastomosis rats were reversed by treatment with ammonia-lowering therapy. Despite significant improvement, molecular and functional readouts were not completely reversed by ammonia-lowering measures. CONCLUSION: Ammonia-lowering therapy results in improvement in skeletal muscle phenotype and function and molecular perturbations of hyperammonemia; these preclinical studies complement previous studies on ammonia-induced skeletal muscle loss and lay the foundation for prolonged ammonia-lowering therapy to reverse sarcopenia of cirrhosis. (Hepatology 2017;65:2045-2058).
引用
- Kumar A, Davuluri G, Silva RNE, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology. 2017. PMID: 28195332. doi:10.1002/hep.29107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。